Clinical efficacy of levonorgestrel releasing intrauterine system for the treatment of adenomyosis in perimenopausal women

Ju-Qi Ma, Chun-Fen Guo, Ayshamgul Hasim
In: Clinical and Experimental Obstetrics & Gynecology · 2018 · vol. 45(3) , pp. 387–390 · doi:10.12891/ceog4098.2018 · W3140186987
Non-randomised trial OA: bronze CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This study found that the levonorgestrel-releasing intrauterine system significantly reduced menstrual blood loss and dysmenorrhea, while improving quality of life in perimenopausal women with adenomyosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text ⓘ

This study evaluated the clinical efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) for menorrhagia, dysmenorrhea, and quality of life in 96 perimenopausal women diagnosed with adenomyosis. After insertion in the postmenstrual phase and follow-up at 1, 3, 6, 12, and 18 months, menstrual blood loss measured by PBAC decreased significantly and dysmenorrhea intensity measured by VAS declined continuously and significantly, with SF-36 scores indicating significant quality-of-life improvement. The study excluded cervical and endometrial lesions via Pap smear, transvaginal sonography, and endometrial biopsy, but the abstract does not specify a control group or randomization and focuses on clinical outcomes only. This paper is centrally about adenomyosis — it assesses LNG-IUS effects on heavy bleeding, pain, and quality of life in perimenopausal women with adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background: The aim of this study was to evaluate the efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of menorrhagia, dysmenorrhea, and poor quality of life caused by adenomyosis in perimenopausal women. Materials and Methods: Ninety-six women with menorrhagia, dysmenorrhea, and poor quality of life with adenomyosis in perimenopausal women were included and were invited to complete a SF-36 Health Survey. Excluded were cervical and endometrial lesions that underwent a Pap smear, transvaginal sonography, and endometrial biopsy. LNG-IUS was inserted in the postmenstrual phase. Blood loss was assessed by pictorial blood loss assessment chart (PBAC), and dysmenorrhea intensity was assessed by a visual analogue scale (VAS). The patients were followed up after one, three, six, 12, and after 18 months. The participations are asked to complete the short form 36 (SF- 36) health survey questionnaires. Results: The menstrual blood size was (60.287 ± 21.832) (41.186 ± 16.153), (30.988 ± 15.670), (19.238 ± 13.649), (16 ± 11.464) after treatment one, three, six, 12, and after 18 months, respectively, which reduced significantly compare with before treatment (88.691 ± 33.775, p p Conclusion: These data suggest that LNG-IUS is a safe and effective option for reduces menorrhagia, relieve dysmenorrhea, and improve the quality of life in patients with adenomyosis from perimenopausal women.
Full text 2,615 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Background: The aim of this study was to evaluate the efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of menorrhagia, dysmenorrhea, and poor quality of life caused by adenomyosis in perimenopausal women. Materials and Methods: Ninety-six women with menorrhagia, dysmenorrhea, and poor quality of life with adenomyosis in perimenopausal women were included and were invited to complete a SF-36 Health Survey. Excluded were cervical and endometrial lesions that underwent a Pap smear, transvaginal sonography, and endometrial biopsy. LNG-IUS was inserted in the postmenstrual phase. Blood loss was assessed by pictorial blood loss assessment chart (PBAC), and dysmenorrhea intensity was assessed by a visual analogue scale (VAS). The patients were followed up after one, three, six, 12, and after 18 months. The participations are asked to complete the short form 36 (SF- 36) health survey questionnaires. Results: The menstrual blood size was (60.287 ± 21.832) (41.186 ± 16.153), (30.988 ± 15.670), (19.238 ± 13.649), (16 ± 11.464) after treatment one, three, six, 12, and after 18 months, respectively, which reduced significantly compare with before treatment (88.691 ± 33.775, p < 0.05). The VAS of dysmenorrheal dropped continuously and significantly from the baseline score of (74.968 ± 15.889) to (38.797 ± 16.781), (24.857 ± 16.595), (15.840 ± 14.305), (10.784 ± 13.593), and (8.196 ± 12.919), respectively, after treatment one, three, six, 12, and after 18 months of the LNG-IUS insertion (p < 0.05). The results of SF-36 Health Survey shown the quality of life was significantly improved. Conclusion: These data suggest that LNG-IUS is a safe and effective option for reduces menorrhagia, relieve dysmenorrhea, and improve the quality of life in patients with adenomyosis from perimenopausal women.

Keywords

- Levonorgestrel intrauterine system - Menorrhagia - Dysmenorrhea - Adenomyosis - Perimenopause - SF-36 Health Survey

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosisdysmenorrhea

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (24)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK